- Home
- RIGL vs HIFS Comparison
RIGL vs HIFS Comparison
Compare RIGL & HIFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- HIFS
- Stock Information
- Founded
- RIGL 1996
- HIFS 1834
- Country
- RIGL United States
- HIFS United States
- Employees
- RIGL N/A
- HIFS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- HIFS Major Banks
- Sector
- RIGL Health Care
- HIFS Finance
- Exchange
- RIGL Nasdaq
- HIFS Nasdaq
- Market Cap
- RIGL 537.6M
- HIFS 598.4M
- IPO Year
- RIGL 2000
- HIFS N/A
- Fundamental
- Price
- RIGL $29.48
- HIFS $305.20
- Analyst Decision
- RIGL Buy
- HIFS
- Analyst Count
- RIGL 5
- HIFS 0
- Target Price
- RIGL $38.20
- HIFS N/A
- AVG Volume (30 Days)
- RIGL 492.6K
- HIFS 117.9K
- Earning Date
- RIGL 11-04-2025
- HIFS 10-10-2025
- Dividend Yield
- RIGL N/A
- HIFS 0.83%
- EPS Growth
- RIGL N/A
- HIFS 94.74
- EPS
- RIGL 5.43
- HIFS 20.54
- Revenue
- RIGL $267,921,000.00
- HIFS $90,528,000.00
- Revenue This Year
- RIGL $59.93
- HIFS N/A
- Revenue Next Year
- RIGL N/A
- HIFS N/A
- P/E Ratio
- RIGL $5.44
- HIFS $14.86
- Revenue Growth
- RIGL 105.62
- HIFS 54.99
- 52 Week Low
- RIGL $13.57
- HIFS $209.71
- 52 Week High
- RIGL $43.72
- HIFS $320.00
- Technical
- Relative Strength Index (RSI)
- RIGL 46.18
- HIFS 58.83
- Support Level
- RIGL $29.30
- HIFS $248.53
- Resistance Level
- RIGL $30.94
- HIFS $304.02
- Average True Range (ATR)
- RIGL 1.26
- HIFS 16.91
- MACD
- RIGL 0.38
- HIFS 3.70
- Stochastic Oscillator
- RIGL 53.61
- HIFS 79.29
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.